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The mechanisms by which TGF-b promotes lung adenocarcinoma (ADC) metastasis are largely unknown. Here,
we report that in lung ADC cells, TGF-b potently induces expression of DOCK4, but not other DOCK family
members, via the Smad pathway and that DOCK4 induction mediates TGF-b’s prometastatic effects by enhancing
tumor cell extravasation. TGF-b-induced DOCK4 stimulates lung ADC cell protrusion, motility, and invasion
without affecting epithelial-to-mesenchymal transition. These processes, which are fundamental to tumor cell
extravasation, are driven by DOCK4-mediated Rac1 activation, unveiling a novel link between TGF-b and Rac1.
Thus, our findings uncover the atypical Rac1 activator DOCK4 as a key component of the TGF-b/Smad pathway
that promotes lung ADC cell extravasation and metastasis.
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The cytokine TGF-b plays an important, albeit complex,
role in epithelial tumorigenesis (Derynck et al. 2001;
Elliott and Blobe 2005; Padua and Massague 2009;
Jakowlew 2010). During early stages of tumorigenesis,
TGF-b typically functions as a tumor suppressor. At later
stages, however, as tumors grow and progress, TGF-b
produced by both tumor and stromal cells within the
tumor microenvironment as a natural response to hyp-
oxic and inflammatory conditions can act as a potent
promoter of multiple steps of the metastatic process.
These include not only local motility/invasion and entry
of cancer cells into the blood stream (intravasation) but
also their exit from the blood vessels (extravasation) and
survival at the distant organ sites (Ma et al. 2008;
Massague 2008; Padua et al. 2008; Giampieri et al.
2009; Padua and Massague 2009; Labelle et al. 2011;
Valastyan and Weinberg 2011; Calon et al. 2012; Yuan
et al. 2014). The relevance of TGF-b signaling for disease
progression has been particularly recognized in tumors
where cancer cells retain the core TGF-b signaling compo-
nents, as is often the case in breast and lung cancers (Kang
et al. 2003; Elliott and Blobe 2005; Massague 2008; Padua
and Massague 2009). Indeed, in lung adenocarcinoma
(ADC), the most common subtype of lung cancer with
a high mortality rate, increased TGF-b1 expression cor-
relates with tumor progression and poor patient survival,
and various experimental model systems support a pro-
metastatic role for TGF-b in these tumors (Lund et al.
1991; Hoffman et al. 2000; Hasegawa et al. 2001; Gibbons
et al. 2009; Nemunaitis et al. 2009; Toonkel et al. 2010;
Provencio et al. 2011; Vazquez et al. 2013).However, amajor
remaining challenge is the identification of TGF-b
target genes that drive the different steps of metastasis,
especially since TGF-b modulates gene expression in
a highly cell- and context-specific manner (Padua and
Massague 2009; Mullen et al. 2011; Massague 2012).
While some progress has been made in the context of
breast cancer metastasis (Michl et al. 2005; Padua et al.
2008; Gregory et al. 2011; Sethi et al. 2011; Shibue et al.
2013), the genes and mechanisms that mediate the
prometastatic effects of TGF-b in lung ADC, particularly
those mediating the extravasation step, remain largely
unknown.
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To explore molecular mechanisms that could mediate
the prometastatic effects of TGF-b in lung ADC, we took
a candidate gene approach and started by scrutinizing
members of the DOCK180-related protein superfamily.
The DOCK180 family, of which a total of 11 mammalian
members have been identified (termedDOCK1/DOCK180
to DOCK11) emerged as a novel class of Rac/Cdc42
GTPase guanine nucleotide exchange factors (GEFs)
(Cote and Vuori 2002; Meller et al. 2005). This class of
proteins has been implicated in diverse cell type-specific
processes (Laurin and Cote 2014), with some of its
members (i.e., DOCK1, DOCK3, and DOCK10) playing
distinct roles in the progression and/or metastasis of
diverse tumor types—including melanoma, breast cancer,
and glioblastoma—by engaging in different protein–
protein interactions (Gadea et al. 2008; Sanz-Moreno
et al. 2008; Feng et al. 2012; Laurin et al. 2013). Whether
any of the DOCK proteins play a role in the progression
and/or metastasis of lung ADC has not been previously
investigated. Our findings presented here demonstrate
that the DOCK4 family member plays a critical role in
mediating TGF-b’s prometastatic effects in lung ADC.
We found that in lung ADC cells, expression of DOCK4,
but not other DOCK180 family members, is rapidly and
robustly induced by TGF-b in a Smad-dependent manner
and that DOCK4 induction is essential for TGF-b-driven
lungADCmetastasis. Blockade of TGF-b-inducedDOCK4
attenuates the ability of lung ADC cells to extravasate
into distant organ sites, resulting in a marked reduction
in metastatic burden in mice. At the cellular level, TGF-
b-induced DOCK4 elicits lung ADC cell protrusive
activity, motility, and invasion and intriguingly does so
via Rac1 activation. So far, Rac1 has been linked to TGF-b
via noncanonical, non-Smad pathways (Zhang 2009).
Thus, our findings identify the atypical Rac1 activator
DOCK4 as a novel, key component of the TGF-b/Smad
pathway that promotes lung ADC cell extravasation and
metastasis.
Results
TGF-b potently induces expression of DOCK4 via the
Smad pathway
Upon examining the expression profiles of all 11 DOCK180
family members in the human lung ADC cell line A549
(subjected or not subjected to TGF-b treatment) by real-
time quantitative PCR (qPCR), we found that all mem-
bers, with the exception of DOCK2, were expressed in
A549 cells. Strikingly, however, only DOCK4 mRNA
levels, but not those of any other DOCK180 family
member, were robustly up-regulated by TGF-b treatment
(Fig. 1A). In addition, we noted DOCK4 to be the most
strongly up-regulated gene among all Rho family GEFs
when analyzing a publically available data set comprising
gene expression profiles of TGF-b-treated A549 cells (NCBI,
Gene Expression Omnibus [GEO] GSE17708) (Supplemen-
tal Fig. 1A). Importantly, TGF-b-induced up-regulation of
DOCK4 was also seen at the protein level (Fig. 1B). The
increase in DOCK4 protein levels was observed in not only
the KRAS mutant A549 cell line but also several other
lung ADC cell lines carrying either a KRAS mutation
(H441) or EGFR mutations (HCC4006, H1975, and PC9)
as well as a KRAS and EGFRwild-type lung ADC cell line
(H1793) (Fig. 1B). All of the above-mentioned cell lines
displayed increased Smad3 phosphorylation levels in re-
sponse to TGF-b (Fig. 1B). Interestingly, no increase in
DOCK4 expression by TGF-b was observed in any of the
TGF-b-responsive breast cancer and melanoma cell lines
that we examined (Supplemental Fig. 1B; data not shown),
suggesting that the effect of TGF-b on DOCK4 expression
is tumor type-dependent. Notably, a recent study also
implicated the WNT/TCF pathway in lung ADC metas-
tasis (Nguyen et al. 2009). However, we did not detect any
change in DOCK4 protein levels upon treatment of A549
cells with WNT3A (Supplemental Fig. 1C), implying that
DOCK4 is not likely a target gene of the WNT/TCF
pathway in lung ADC metastasis.
A key pathway in the regulation of TGF-b-induced
gene expression is the canonical Smad pathway, albeit
noncanonical non-Smad pathways have been implicated
as well (Padua and Massague 2009; Zhang 2009). To
explore whether the Smad pathway is responsible for
TGF-b-induced DOCK4 up-regulation, we used two pre-
viously described Smad4 shRNAs (shSmad4#1 and
shSmad4#2) that we confirmed to be effective in reducing
Smad4 protein levels (Fig. 1C; Supplemental Fig. 1D).
Smad4 is an essential component of the Smad pathway;
upon TGF-b stimulation, it forms complexes with
receptor-phosphorylated Smad2/Smad3 proteins, which
translocate into the nucleus and regulate gene transcrip-
tion (Padua and Massague 2009). Stable A549 and
HCC4006 cell lines expressing shSmad4#1, shSmad4#2,
or control shRNA (shCtrl) were generated and subjected
to TGF-b treatment. As expected, in shCtrl-expressing
cells, TGF-b triggered a robust increase in DOCK4
expression. This increase, however, was largely prevented
in shSmad4#1- and shSmad4#2-expressing cells (Fig. 1D,
E; Supplemental Fig. 1D,E). Moreover, when we used the
Smad3 inhibitor SIS3 or the TGF-b type I receptor in-
hibitor SB432542 to interfere with the TGF-b/Smad
pathway, we similarly found that SIS3 and SB432542
blocked the TGF-b-induced increase in DOCK4 expres-
sion (Fig. 1F–H; Supplemental Fig. 1F). Notably, DOCK4
mRNA up-regulation was also seen upon acute TGF-b
treatment (3 and 7 h) and was entirely abrogated when
cells were treated with the transcription inhibitor acti-
nomycin D (Supplemental Fig. 1G). These data indicate
that TGF-b transcriptionally up-regulates DOCK4 in
lung ADC cells via the canonical Smad pathway.
To evaluate whether DOCK4 is a direct target of the
TGF-b/Smad pathway, we first tested whether new pro-
tein synthesis is required for TGF-b-induced transcrip-
tional activation of DOCK4. We found that treatment of
A549 cells with the protein synthesis inhibitor cyclohex-
imide (CHX) did not prevent TGF-b-induced up-regulation
of DOCK4 mRNA (Supplemental Fig. 1H), indicating that
increased DOCK4 expression is not a secondary effect of
TGF-b/Smad signaling activation. We next searched for
potential Smad-binding elements (SBEs) in the DOCK4
DOCK4 in TGF-b-induced lung ADC metastasis
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promoter region using TRANSFAC and FIMO from the
MEME suite (Grant et al. 2011). However, we did not
detect any canonical SBEs within 20 kb of the DOCK4
transcriptional start site (data not shown). Since prior
studies had shown that a large proportion of Smad-binding
sites are found outside of promoter-proximal regions at
putative enhancer elements (Kennedy et al. 2011;Morikawa
et al. 2011; Schlenner et al. 2012; Gaunt et al. 2013), we
considered whether Smad proteins occupy distal SBEs at the
DOCK4 locus. To this end, we analyzed available Smad3
Figure 1. TGF-b induces DOCK4 expression in human lung ADC cells via the Smad pathway. (A) qPCR analysis of DOCK180 family
member mRNAs in A549 cells treated with 2 ng/mLTGF-b. (B) Western blot analysis of DOCK4, p-Smad3, and Smad3 in human lung
ADC cell lines treated with TGF-b. DOCK4 levels were normalized to Gapdh and then to a value of 1.0 for day 0. (C) Western blot
analysis of Smad4 in A549 cells stably expressing shCtrl or shSmad4#1. (*) Nonspecific band. (D,E) Western blot analysis of DOCK4 and
E-cadherin (D) and qPCR analysis of DOCK4 mRNA (E) in shCtrl- and shSmad4#1-expressing A549 cells treated with TGF-b. (F,G)
Western blot analysis of DOCK4, p-Smad3, and Smad3 (F) and qPCR analysis of DOCK4 mRNA (G) in A549 cells treated with 10 mM
p-Smad3 inhibitor SIS3 and/or 2 ng/mLTGF-b for 24 h. (H) Western blot analysis of DOCK4, p-Smad3, and Smad3 in A549 cells treated
with 0–10 mM TGF-b type I receptor inhibitor SB431542 and 2 ng/mL TGF-b for 24 h. qPCR data in A, E, and G were normalized to
Gapdh and are presented as mean 6 SD. n = 3. (*) P < 0.05; (**) P < 0.01 by an unpaired two-tailed Student’s t-test. (I, top) ChIP-seq
occupancy profile of Smad3 along with input DNA on human DOCK4 locus obtained in A549 cells shown in reads per half-million.
MACS peaks depict two validated peaks with a false discovery rate (FDR) <5%. Data were obtained from the GEO database (GSE51509).
(Bottom) Validated transcript models for DOCK4 from the hg18 genome assembly. (Black bars) Exons; (blue bars) Smad-binding
elements (SBEs) within the corresponding MACS peaks; (TSS) transcriptional start site. (J) ChIP assay for p-Smad3 binding to two SBEs
in the first intron of DOCK4. A549 and MDA-MB-231 cells left untreated or treated with 2 ng/mL TGF-b for 5 h were harvested and
processed for ChIP with isogenic IgG or anti-p-Smad3 antibody. The enrichment of the precipitated DNA by p-Smad3 antibody versus
the IgG was analyzed by qPCR using primers flanking SBE1 and SBE2. Data are shown as fold of DNA enrichment and presented as
mean 6 SD. n = 3.
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ChIP-seq (chromatin immunoprecipitation [ChIP] com-
bined with deep sequencing) data (GSE51509) obtained
from TGF-b-stimulated A549 cells (Isogaya et al. 2014)
and found two significant Smad3 peaks in the first intron
of DOCK4 at +45 kb and +125 kb (Fig. 1I). Notably, each
of these two sites contains a single SBE. To test whether
p-Smad3 directly binds to the two putative SBEs, we
designed primers flanking the two putative SBEs and
performed anti-p-Smad3 ChIP followed by qRT–PCR
(ChIP-qPCR). We found that p-Smad3 binds to both SBEs
in a TGF-b-dependent manner (Fig. 1J). Importantly,
binding of p-Smad3 to the two SBEs was detected in lung
ADC A549 cells, but not in breast cancer MDA-MD-231
cells (Fig. 1J), in which no TGF-b-induced up-regulation of
DOCK4 was observed (Supplemental Fig. 1B). Taken
together, these data strongly suggest that DOCK4 is
a direct TGF-b/Smad target gene in lung ADC cells.
High DOCK4 expression correlates with Smad
activation and poor prognosis in human lung ADC
To extend our findings beyond cells in culture and determine
a possible relevance to human lung ADC disease, we
examined whether the levels of DOCK4 and p-Smad3 (used
as a readout for activity of TGF-b signaling)were correlated in
human lung ADC. To this end, we performed immunohisto-
chemistry (IHC) on human lung ADC tissue microarrays
(TMAs) using anti-DOCK4-specific and anti-p-Smad3-specific
antibodies (Supplemental Fig. 2A; Siebert et al. 2011). We
observed that DOCK4 expression was significantly higher
in tumor tissues compared with adjacent normal tissues
(Supplemental Fig. 2B,C). Moreover and importantly, we
observed a strong and significant positive correlation
between DOCK4 and p-Smad3 levels in the tumor tissues
(Fig. 2A,B), indicating that DOCK4 levels positively corre-
late with activated TGF-b signaling in human lung ADC.
We further investigated whether DOCK4 expression
was correlated with the clinical outcome of human lung
ADC. To this end, we analyzed a publicly available
microarray data set containing gene expression profiles
of 182 human lung ADCs and clinical follow-up infor-
mation. Both Cox proportional univariate and multivar-
iate analyses revealed an inverse correlation between
DOCK4 expression and patient recurrence-free survival
(Fig. 2C,D; Supplemental Table 3). Moreover, contingency
analyses revealed that high DOCK4 expression is strongly
correlated with high frequency of recurrence events and
weakly but significantly correlated with advanced tumor
stage (stage III or higher) (Supplemental Table 4). Notably,
no such correlationswere observed forDOCK3 expression;
DOCK3 is the most closely related to DOCK4 family
member (Supplemental Fig. 3A,B; Supplemental Table 3).
Also, upon analyzing publicly available breast cancer data
sets, no inverse correlation between DOCK4 expression
and patient recurrence-free survival was observed (Supple-
mental Fig 3C,D), consistent with our findings that TGF-b
does not induce DOCK4 expression in breast cancer cell
lines. Together, these results suggest that DOCK4 is
a potential prognostic factor that predicts disease relapse
in human lung ADC patients.
DOCK4 is required for TGF-b’s prometastatic effects
in lung ADC
Based on our above findings and previous reports corre-
lating increased TGF-b expression with tumor progres-
sion and metastasis in lung ADC (Hasegawa et al. 2001;
Nemunaitis et al. 2009; Vazquez et al. 2013), we next
asked whether DOCK4 mediates the prometastatic ef-
fects of TGF-b in lung ADC. To address this, we first
established an experimental model for the analysis of
lung ADC metastasis. Because lung ADC typically me-
tastasizes to multiple organs (including bones, the adre-
nal glands, the brain, and the liver) (Nguyen et al. 2009),
with lung ADC cells released from the primary site
traveling via the arterial circulation to distant organ sites,
Figure 2. DOCK4 expression is correlated with
activity of TGF-b signaling and recurrence-free
survival in lung ADC. (A) Representative images
of IHC stainings for p-Smad3 and DOCK4 in
human lung ADC TMAs. Nuclei were counter-
stained with hematoxylin. Boxed regions are
enlarged and shown at the right. Bars, 250 mm.
(B) Percentage of human lung ADC samples
displaying low or high DOCK4 expression in the
low or high p-Smad3 expression group. (**) P <
0.01 by Fisher’s exact test. (C) Hazard ratio plot in
function of DOCK4 expression based on gene
expression and recurrence-free survival data for
a cohort of 182 lung ADC patients. The dotted
line indicates the cutoff that yields the highest
hazard ratio with confidence interval 95% to
define the low/high DOCK4 expression groups.
(D) Kaplan-Meier survival curve for the low/high
DOCK4 expression groups indicated in C. The
P-value was calculated by log rank test.
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we opted to use an intracardiac injection model of exper-
imental metastasis in which cancer cells are injected into
the left cardiac ventricle of NOD/SCID-IL2g (NSG) mice
(Fig. 3A). Using this model, we assessed the metastatic
potential of both A549 (KRAS mutant) and HCC4006
(EGFR mutant) cells and evaluated whether pre-exposure
of these cells to TGF-b prior to their introduction into the
arterial circulation (to ‘‘mimic’’ the source of TGF-b that
tumor cells normally experience within the primary
tumor microenvironment) increases their metastatic po-
tential. Specifically, A549 and HCC4006 cells engineered
to stably express firefly luciferase (A549-luc and HCC4006-
luc) were either left untreated or treated with TGF-b for 24
h and placed in the arterial circulation of NSG mice by
intracardiac injection. Mice were subsequently monitored
for multiorgan metastasis by bioluminescence imaging.
While both untreated A549-luc and HCC4006-luc cells
formed some metastases in multiple organs—with A549-
luc cells preferentially colonizing the liver and bone, and
HCC4006-luc cells colonizing the adrenal glands—we
noted that the metastatic burden in animals was mark-
edly increased when the A549-luc and HCC4006-luc cells
were pretreated with TGF-b prior to injection (Fig. 3B),
indicating that TGF-b stimulation enhances the meta-
static potential of both lung ADC cell lines. Metastases in
the adrenal glands, bones, and the liver were confirmed by
ex vivo bioluminescence imaging and histology (Fig. 3C).
Having established an experimental model for lung
ADC metastasis, we next assessed the requirement of
DOCK4 in TGF-b-driven lung ADC metastasis. To ap-
proach this, we generated a retroviral vector that coex-
presses EGFP and a miR-30-based shRNA targeting the 39
untranslated region (UTR) of DOCK4 mRNA (shDock4#1).
This shRNA substantially reduced DOCK4 protein levels
Figure 3. DOCK4 is required for TGF-b-driven
lung ADC metastasis. (A) Schematic drawing of
intracardiac injection. (B) Bioluminescent (BLU)
images of NSG mice intracardially injected with
TGF-b-pretreated (24 h, +) or untreated () A549
and HCC4006 cells taken at the indicated days
after injection. (C) BLU images and H&E staining
of metastases in the indicated organs harvested
from the mice in B. Bars, 200 mm. (D) Western
blot analysis of DOCK4 in A549 cells expressing
the indicated constructs. (E) Growth curve of
TGF-b-pretreated (24 h, +) or untreated () A549
cells stably expressing shCtrl or shDock4#1.
Data represent mean 6 SD. n = 3. (F) Analysis
of lung tumor growth in NSG mice intrathorac-
ically injected with TGF-b-pretreated (24 h, +) or
untreated () A549 cells expressing shCtrl or
shDock4#1. (Top) Dot plots of lung photon flux
at days 7 and 14. BLU signals were normalized to
day 0. (Bottom) Representative images of mice
with lung tumors. n = 6–9 mice per condition.
(G,H) Analysis of metastatic burden in NSG
mice intracardially injected with TGF-b-pre-
treated (24 h, +) or untreated () A549 (G) or
HCC4006 (H) cells expressing the indicated
constructs. (Top) Dot plots of metastatic burden
at day 14 (A549) and day 35 (HCC4006). BLU
signals were normalized to day 0 and then to
a value of 100 for control conditions (shCtrl,
TGF-b). (Bottom) Representative images of
mice with metastases. n = 7–10 (G) and 7–11
(H) mice per condition. P-values in F–H were
calculated by an unpaired Mann-Whitney test.
(**) P < 0.01; (***) P < 0.001; (n.s.) P $ 0.05.
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when stably introduced into A549-luc or HCC4006-luc
cells, whereas shCtrl had no effect. Moreover and impor-
tantly, shDock4#1 largely blunted induction of DOCK4
expression by TGF-b (Fig. 3D; Supplemental Fig. 4A).
Before assessing the metastatic potential of the shRNA-
expressing cells, we first scrutinized their proliferative
properties, especially since DOCK4 had been reported to
display tumor-suppressive activity in osteosarcoma cells
(Yajnik et al. 2003). We found that DOCK4 knockdown
did not affect the growth rate of A549 or HCC4006 lung
ADC cells regardless of them being pretreated with TGF-b
(Fig. 3E; Supplemental Fig. 4B). Moreover, when shRNA-
expressing cells pretreated or not pretreated with TGF-b
were implanted into the lungs of NSG mice via intratho-
racic injection, no difference in tumor growth rate was
observed among the four experimental groups (Fig. 3F),
indicating that DOCK4 knockdown does not affect the
ability of these cells to form primary pulmonary tumors.
Also, DOCK4 knockdown did not affect the survival of
these cells in either monolayer or suspension culture
(Supplemental Fig. 4C,D; data not shown).
We then injected the shRNA-expressing cells, pretreated
or not pretreated with TGF-b, into the arterial circulation
of NSG mice and monitored the mice for metastases.
Strikingly, DOCK4 knockdown markedly blunted the pro-
metastatic effects of TGF-b in bothA549 andHCC4006 cells.
Compared with animals injected with TGF-b-pretreated
shCtrl-expressing cells, the metastatic burden in animals
injected with TGF-b-pretreated shDock4#1-expressing
cells wasmarkedly reduced (Fig. 3G,H). Importantly, rescue
experiments using DOCK4 cDNA that lacks the 39 UTR
and therefore is resistant to Dock4 shRNA-mediated RNAi
(Fig. 3D) demonstrated that the effects of DOCK4 RNAi
were specific (Fig. 3G, Rescue). Expression of DOCK4 alone
(to levels similar to those induced by TGF-b) did not alter
the metastatic potential or growth properties of lung ADC
cells and, accordingly, did not affect the metastatic burden
in animals (Supplemental Fig 5A–C), implying that path-
ways parallel to DOCK4 contribute to TGF-b’s prometa-
static effects (see further below). Of note, we also saw
a slight decrease in metastatic burden in animals injected
with TGF-b-untreated shDock4#1-expressing cells as
compared with animals injected with untreated shCtrl-
expressing cells (Fig. 3G,H).We presume that the lung ADC
cells, when placed in circulation, can still become exposed
to TGF-b signals provided by platelets in the bloodstream
(Labelle et al. 2011). Clearly, though, compared with TGF-
b-pretreated lung ADC cells, the metastatic efficiency of
untreated cells is much lower, supporting the notion that
pre-exposure of cells to TGF-b (‘‘mimicking’’ the source of
TGF-b at the primary site) primes these cells for efficient
metastasis as they enter the circulation. Together, these
data unveil an essential role for DOCK4 in mediating the
metastasis-promoting activity of TGF-b in lung ADC cells
from circulation to distant organ sites.
DOCK4 depletion inhibits TGF-b-driven lung ADC
cell extravasation
For circulating cancer cells to establish distant metasta-
ses, they must leave the circulation in a process called
extravasation at distant organ sites and then, after in-
filtrating the new tissue, must acquire the ability to
survive and proliferate in this new microenvironment
in order to form macroscopic metastases (Valastyan and
Weinberg 2011; Scott et al. 2012). To explore whether
depletion of DOCK4 in TGF-b-primed lung ADC cells
impacts their extravasation capabilities and/or their abil-
ity to survive/proliferate at the distant organ sites, we
began by scoring the number and size of metastatic
nodules formed in the livers of mice that were intracardi-
ally injectedwith TGF-b-pretreated or untreated shCtrl- or
shDock4#1-expressing A549-luc cells (Fig. 4A). In line
with our above findings, pretreatment of shCtrl-expressing
cells, but not of shDock4#1-expressing cells, with TGF-b
prior to injection led to a marked increase in the number
of metastatic nodules (Fig. 4A). Interestingly, though, the
size of the metastatic nodules that developed in the livers
was not significantly different among the four experi-
mental groups (Fig. 4B), implying that TGF-b pretreat-
ment and, importantly, DOCK4 depletion do not alter the
capacity of lung ADC cells to grow in the new microen-
vironment. To substantiate this, we first checked that the
liver metastases formed from shDock4#1-expressing cells
were not attributable to proliferation of tumor cells that
lost shRNA expression. To this end, we extracted EGFP-
labeled tumor cells from liver metastases originating
from TGF-b-pretreated shCtrl- and shDock4#1-express-
ing A549-luc cells (referred to as liver mets-derived cells)
and assessed DOCK4 levels by Western blot analysis. We
found that DOCK4 levels were still efficiently knocked
down in these cells (Fig. 4C). Moreover, when we assessed
their proliferative properties in vitro, we did not detect
any differences between the growth rates of shDock4#1- and
shCtrl-expressing liver mets-derived cells (Fig. 4D). In addi-
tion, when we injected shDock4#1- or shCtrl-expressing
A549-luc cells pretreated or not pretreated with TGF-b
into livers of NSG mice and evaluated tumor growth
7 and 14 d following injection, we found that the growth
rate of the tumors was similar among all of the experi-
mental groups (Fig. 4E). Thus, DOCK4 depletion in TGF-
b-primed lung ADC cells does not affect their ability to
survive/proliferate in a new microenvironment.
Hence, we next assessed whether TGF-b/DOCK4 sig-
naling influences the capacity of lung ADC cells to
extravasate into distant target organs. To this end, we
isolated livers from NSG mice that were sacrificed 20 h
after intracardiac injection with TGF-b-pretreated or un-
treated shCtrl- or shDock4#1-expressing A549-luc cells.
Of note, we chose the liver because it is a relatively large
and highly vascularized organ. Livers were perfused, and
liver sections were immunostained for GFP and CD31 to
visualize tumor cells and liver vasculature, respectively
(Fig. 4F). The percentages of tumor cells inside (intravas-
cular) and outside (extravascular) the blood vessels were
then quantified (Fig. 4G). We found that the fraction of
tumor cells that extravasated out of the liver vasculature
was markedly increased in the TGF-b-pretreated shCtrl
group as compared with the untreated shCtrl group,
supporting the notion that TGF-b promotes tumor cell
extravasation. However, no such increase was observed
DOCK4 in TGF-b-induced lung ADC metastasis
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in the TGF-b-pretreated shDock4#1 group, where, similar
to the untreated shDock4#1 and shCtrl groups, the major-
ity of tumor cells remained in the blood vessels (Fig. 4G),
indicating that DOCK4 function is required for TGF-b’s
enhancing effect on tumor cell extravasation. Notably,
DOCK4 levels remained high in the TGF-b-pretreated
cells for at least 48 h following TGF-b removal (Supple-
mental Fig. 6), which is well within the time period needed
for these cells to extravasate following intracardiac in-
jection. Combined, these data establish a critical role for
the TGF-b/DOCK4 signaling axis in the regulation of lung
ADC cell extravasation and metastasis in vivo.
DOCK4 mediates TGF-b’s enhancing effects on lung
ADC cell protrusive activity, motility, and invasion,
but not epithelial–mesenchymal transition (EMT), via
Rac1 activation
We next sought to gain further insight into the cellular
mechanisms by which DOCK4 mediates TGF-b’s enhanc-
ing effect on tumor cell extravasation and metastasis.
Although the cellular underpinnings of tumor cell ex-
travasation still remain poorly understood, increasing
evidence indicates that it is a dynamic process involving
changes in not only the vascular endothelium but also the
tumor cells during their intravascular transit to the sites
of metastasis, with tumor cells undergoing changes in
cell shape and migratory behavior (Strell and Entschladen
2008; Stoletov et al. 2010; Reymond et al. 2013). TGF-b
has been implicated inmost of these processes (Giampieri
et al. 2009; Valastyan and Weinberg 2011), and, interest-
ingly, recent studies reported that TGF-b-induced EMT
not only facilitates tumor cells to intravasate but also
helps them to extravasate (Stoletov et al. 2010; Labelle
et al. 2011; Tsai and Yang 2013; Yu et al. 2013). Based on
these findings, we first explored whether DOCK4 affects
TGF-b-induced EMT in A549 and HCC4006 lung ADC
cells. To this end, we examined the impact of DOCK4
knockdown on the expression levels of TGF-b-responsive
genes known to be involved in EMT (including E-cadherin,
Vimentin, Snail, Slug, Twist1, and Zeb1/2) (Valastyan and
Figure 4. DOCK4 depletion inhibits TGF-
b-driven lung ADC cell extravasation but does
not affect the ability of lung ADC cells to grow in
distant organs. (A) Quantification of the number
of metastatic nodules in the liver after intracar-
diac injection of TGF-b-pretreated (24 h, +) or
untreated () A549 cells expressing shCtrl or
shDock4#1. (Top) Number of metastatic nodules
on the liver surface. n = 5 livers per condition.
(Bottom) Representative images of livers. Boxed
regions are enlarged and shown in the bottom
row. Bars, 1 cm. (B) Quantification of size (by
measuring diameter) of metastatic nodules in
H&E-stained liver sections from the mice in A.
n = 120 per condition. Data in A and B represent
mean 6 SD. (C) Western blot analysis of DOCK4
protein expression in A549 parental and liver
mets-derived cells. Gapdh was used as a loading
control. (D) Growth curve of shCtrl- and
shDock4#1-expressing A549 liver mets-derived
cells. Data represent mean 6 SD. n = 3. (E)
Analysis of tumor growth in livers of NSG mice
intrahepatically injected with TGF-b-pretreated
(24 h, +) or untreated () A549 cells expressing
shCtrl or shDock4#1. (Top) Dot plots of liver
photon flux at days 7 and 14, normalized to
day 0. (Bottom) Representative images of mice
with liver tumors. n = 8–9 mice per condition.
P-values in A, B, and E were calculated by an
unpaired Mann-Whitney test. (n.s.) P $ 0.05. (F)
Representative confocal images of liver sections
depicting tumor cells inside (intravascular) or
outside (extravascular) blood vessels obtained
from NSG mice 20 h after intracardiac injection
with the cells in A. Bars, 20 mm. (G) Percentage of
intravascular or extravascular A549 cells from
the experiment shown in F. n = 31–40 cells per
condition. (*) P < 0.05 by Fisher’s exact test.
Yu et al.
256 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on November 3, 2017 - Published by genesdev.cshlp.orgDownloaded from 
Weinberg 2011). In both cell lines, TGF-b induced
a down-regulation and/or cytoplasmic translocation of
E-cadherin and an up-regulation of Vimentin, Snail, and
Slug as well as an EMT phenotype (Fig. 5A; Supplemental
Fig. 7A–D). Knockdown of DOCK4 did not affect any of
the TGF-b-induced changes in EMT markers and did not
prevent the acquisition of a mesenchymal-like phenotype
(Supplemental Fig. 7A–D). Also, ectopic expression of
DOCK4 did not alter any of these properties (Supplemen-
tal Fig. 7E; data not shown). These data indicate that
DOCK4 is dispensable for TGF-b-induced EMT in A549
and HCC4006 lung ADC cells and further imply that
TGF-b drives EMT and DOCK4 induction via parallel
pathways.
Figure 5. DOCK4 mediates TGF-b’s enhancing effects on lung ADC cell protrusive activity, motility, and invasion, but not EMT, via
Rac1 activation. (A) qPCR analysis of mRNAs of EMT markers in shCtrl- and shDock4#1-expressing A549 cells treated with TGF-b.
Data represent mean 6 SD. n = 3. (B) Representative movement trajectories of single shCtrl- or shDock4#1-expressing A549 cells left
untreated or pretreated (for 24 h) with TGF-b obtained over 4.5 h. (C) Quantification of movement velocity of shDock4#1- and
shDock4#2-expressing A549 cells. n = 33–44 cells per condition. (D) Quantification of Matrigel invasion assays of shDock4#1- and
shDock4#2-expressing A549 cells. Data represent mean6 SD. n = 5 transwells per group. (E) Representative images of single A549 cells
expressing the indicated constructs, left untreated or pretreated with TGF-b for 24 h, obtained from live-cell imaging at the indicated
time points. Bars, 50 mm. (F) Quantification of movement velocity of the cells in E. n = 36–56 cells per condition. Data in C and F are
presented as Tukey box plots. P-values in C, D, and F were calculated by an unpaired Mann-Whitney test. (G) Percentage of cells with
a large protrusion over a 30-min time interval. n = 6 fields containing 104–151 cells per condition. Data represent mean 6 SD. P-values
were calculated using an unpaired two-tailed Student’s t-test. (*) P < 0.05; (**) P < 0.01; (***) P < 0.001; (****) P < 0.0001; (n.s.) P$ 0.05.
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We next assessed whether DOCK4 knockdown influ-
ences the migratory and invasive behavior of the lung
ADC cells. Since the majority of circulating tumor cells
appears to consist of single cells (Yu et al. 2013), we
tracked the movement of single cells pretreated or not
pretreated with TGF-b. We observed that TGF-b pre-
treatment of shCtrl-expressing A549 or HCC4006 cells
greatly enhanced the motility of these cells and that this
enhancement was abrogated upon inhibition of the TGF-
b/Smad pathway (Fig. 5B,C; Supplemental Fig. 8B–E).
Importantly, while DOCK4 knockdown using two in-
dependent shRNAs (shDock4#1 and shDock4#2) did not
affect the basal levels of A549 or HCC4006 cell motility,
it impeded, similarly to as seen for TGF-b/Smad inhibi-
tion, the TGF-b-induced increase in cell motility (Fig. 5B,C;
Supplemental Fig. 8A–E). We further examined the in-
vasive potential of these cells using a Matrigel-coated
Boyden chamber assay, given that tumor cells must
invade the basement membrane surrounding the blood
vessels to enter the parenchyma of their target organs
(Reymond et al. 2013). While TGF-b treatment of shCtrl-
expressing A549 cells resulted in a robust increase in
invasion through Matrigel, only a very modest increase
was observed when shDock4#1- or shDock4#2-expressing
cells were treated with TGF-b (Fig. 5D). Thus, DOCK4
function is essential for TGF-b’s stimulating effects on
lung ADC cell motility and invasion. Of note, a role for
DOCK4 in the migration of distinct cell types had been
reported previously (Hiramoto et al. 2006; Kawada et al.
2009; Kobayashi et al. 2014). Interestingly, a closer scrutiny
of themorphology of the shRNA-expressing cells in our live-
cell imaging experiments revealed that TGF-b-pretreated
shCtrl-expressing cells displayed higher membrane pro-
trusive activity than the untreated shCtrl-expressing
cells, with TGF-b-pretreated cells extending a large for-
ward protrusion (Fig. 5E,G). In contrast, while shDock4#1-
and shDock4#2-expressing cells did undergo EMT when
exposed to TGF-b, they hardly extended forward protru-
sions (Fig. 5E,G; data not shown), indicating that DOCK4’s
function is important for TGF-b-promoted mesenchymal
cancer cell protrusive activity.
Finally, we asked whether DOCK4 exerts its cellular
effects by acting on the Rac1 signaling pathway or,
potentially, other pathways. On the one hand, Rac1
activation has been implicated in cell motility and pro-
trusion extension during transendothelial migration
(Reymond et al. 2013); on the other hand, however, we
found that TGF-b induces DOCK4 expression via the
canonical Smad pathway, and so far Rac1 has beenmainly
linked to TGF-b via noncanonical pathways (Zhang
2009). Hence, we first determined whether Rac1 activa-
tion is mediated via the TGF-b/Smad/DOCK4 pathway
in lung ADC cells. While TGF-b triggered a robust in-
crease in Rac1 activity in shCtrl-expressing A549 cells,
we found that this increase was greatly reduced in both
shSmad4#2- and shDock4#1-expressing A549 cells (Sup-
plemental Fig. 9A,B,D). Of note, DOCK4 knockdown did
not affect TGF-b-induced activation of Rap1 or Cdc42 in
A549 cells (Supplemental Fig. 9C). Furthermore, we
found that the DHR2 domain of DOCK4, which is
conserved among all DOCK180 family members and
catalyzes the exchange of GDP for GTP on Rac1 (Cote
and Vuori 2002; Meller et al. 2005), is essential for TGF-
b-elicited Rac1 activation in A549 cells. Indeed, intro-
duction of DOCK4WT, but not a DOCK4DDHR2 mutant
lacking 77 amino acids within the DHR2 domain (Kawada
et al. 2009), in shDock4#-expressing cells restored the
levels of TGF-b-induced Rac1 activation to that seen in
control cells (Supplemental Fig. 9A,B). Thus, DOCK4 links
the canonical TGF-b/Smad pathway to Rac1 activation in
lung ADC cells. These findings prompted us to investi-
gate whether DOCK4 exerts its cellular effects via
activation of the Rac1 pathway. We first examined the
ability of DOCK4DDHR2 to rescue the impaired protrusive
activity and cell motility observed in the TGF-b-treated
shDock4#1-expressing cells. While DOCK4WT was able
to fully rescue these phenotypes, DOCK4DDHR2 failed
to do so (Fig. 5E–G), indicating that DOCK4’s Rac-GEF
activity is essential for its function in mediating TGF-b’s
effects on cell motility and protrusion formation. Of note,
expression of DOCK4WT alone did not affect the motility
or protrusive activity of these cells (Supplemental Fig. 8F),
consistent with our findings that it does not affect their
metastatic potential. We next examined whether con-
comitant expression of an activated mutant form of Rac1
(Rac1Q61L) with shDock4#1 could rescue the DOCK4
RNAi-produced phenotypes and found that this is indeed
the case. Cells coexpressing shDock4#1 and Rac1Q61L
extended protrusions and displayed increased cell motil-
ity upon TGF-b treatment (Fig. 5E–G). Finally, we in-
vestigated whether knockdown of Rac1 phenocopies the
effects of DOCK4 down-regulation on TGF-b-promoted
cell motility and protrusive activity. To this end, we took
advantage of two previously described shRNAs, shRac1#1
and shRac1#2 (Akunuru et al. 2011), with shRac1#1 being
more effective than shRac1#2 (Supplemental Fig. 9E). We
found that both shRac1#1 and shRac1#2 interfered with
a TGF-b-induced increase in cell motility and protrusive
activity, with shRac1#1 beingmore effective than shRac1#2
(Supplemental Fig. 9F; data not shown), as expected. Thus,
DOCK4 links the canonical TGF-b/Smad pathway to the
Rac1 pathway in the regulation of lung ADC cell shape and
migratory behavior, processes fundamental to tumor cell
extravasation and metastasis. Notably, a previous study
reported that DOCK3 forms a complex with NEDD9 and
that this complex regulates Rac1 activation to drive mes-
enchymal movement in melanoma cells (Sanz-Moreno
et al. 2008). However, we found that DOCK4, while
effectively activating Rac1, does not interact with NEDD9
(Supplemental Fig. 10A,B), further supporting the notion
that these two proteins have distinct modes of regulation
and likely serve distinctive cell type-specific functions.
Discussion
Metastasis from lung ADC, the most common subtype of
lung cancer, typically occurs rapidly to multiple organs
(Hoffman et al. 2000; Provencio et al. 2011). A key factor
reported to drive lung ADC metastasis is the cytokine
TGF-b (Lund et al. 1991; Hasegawa et al. 2001;Nemunaitis
Yu et al.
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et al. 2009; Toonkel et al. 2010; Vazquez et al. 2013);
however, the genes and mechanisms that mediate the
prometastatic effects of TGF-b remain largely unknown.
Here we identify DOCK4 as a novel, key target of the
TGF-b/Smad signaling pathway that promotes lung ADC
metastasis by enhancing the competence of lung ADC
cells to extravasate into distant organs. We further
present evidence that DOCK4 does so at least in part by
stimulating the protrusive activity and motility of mes-
enchymal lung ADC cells via activation of the Rac1
pathway.
DOCK4 is a member of the DOCK180 family of GEFs,
of which a total of 11 mammalian family members have
been identified (Cote and Vuori 2002; Meller et al. 2005).
While all members, with the exception of DOCK2, are
expressed in lung ADC cells, we found that the TGF-
b/Smad pathway selectively up-regulates the expression
of DOCK4 but not other DOCK family members, sup-
porting the notion that these proteins exhibit different
modes of regulation (Laurin and Cote 2014). Notably,
high DOCK4 expression levels correlate with activated
TGF-b signaling and poor prognosis in human lung ADC.
Interestingly, the regulation of DOCK4 by TGF-b appears
to be tumor type-dependent. Indeed, no induction of
DOCK4 by TGF-b was observed in breast cancer and
melanoma cells. Also, binding of p-Smad3 to SBEs within
DOCK4’s first intron was detected in lung ADC cells but
not in breast cancer cells. Finally, no correlation between
DOCK4 expression and disease relapse was found in
estrogen receptor (ER)-negative breast cancer patients.
One possible explanation for these context-dependent
observations is that the epigenetic status of lung ADC
cells is different from that of breast cancer and melanoma
cells. Also, cell type-specific Smad cofactors critical to the
regulation of DOCK4 expression in response to TGF-b
signaling could be present in lung ADC cells but not in
breast cancer and melanoma cells. Future studies will be
required to decipher the precise cell/tumor type-specific
regulation of DOCK4 expression in response to TGF-
b/Smad signaling.
Using xenograft mouse models, we showed that
DOCK4 plays a critical role in mediating TGF-b-driven
lung ADC metastasis. An intriguing finding from our
studies is that while DOCK4 expression is already in-
duced by TGF-b in primary human lung ADC (as in-
dicated by our IHC stainings of human lung ADC TMAs),
DOCK4 appears to exert its effects at a later time by
enhancing the extravasation capabilities of lung ADC
cells. Indeed, we found that DOCK4 knockdown in TGF-
b-primed lung ADC cells that are about to enter circula-
tion impedes their ability to form metastatic foci at the
distant organ sites and that DOCK4 exerts this effect
without affecting the growth properties or survival of the
metastasizing cells. Moreover, we observed that the
fraction of TGF-b-primed lung ADC cells that extrava-
sated out of the liver vasculature was markedly reduced
in the DOCK4 knockdown group compared with the
control group. These findings reinforce the view that
TGF-b signals produced within the primary tumor mi-
croenvironment can influence later stages of metastasis
and that a protein induced by TGF-b in tumor cells at the
primary site may also act at a later step of the metastatic
process (Padua et al. 2008; Calon et al. 2012; Yuan et al.
2014). Our data, however, do not exclude that DOCK4
could also play a role in mediating the enhancing effect of
TGF-b on lung ADC cell intravasation. Future studies
will be required to determine whether DOCK4 acts on
not only the late steps but also the early steps of lung
ADC metastasis.
Padua et al. (2008) previously showed that TGF-b in
the breast tumor microenvironment primes tumor cells
for metastasis to the lungs by driving the expression
of angiopoietin-like 4 (ANGPTL4). Interestingly, while
ANGPTL4 facilitates tumor cell extravasation in a non-
cell-autonomous manner by disrupting endothelial junc-
tions at themetastatic sites, our data indicate thatDOCK4
does so in a cell-autonomous manner by promoting the
protrusive activity and motility of lung ADC cells.
Notably, a recent in vivo study showed that tumor cells
with high protrusive activity can migrate and navigate
through narrow vessel lumen openings and vessel branch
points, a process that could allow them to find optimal
sites for extravasation (Stoletov et al. 2010). Combined,
these findings indicate that tumor cell extravasation is
a highly dynamic and coordinated process involving
contributions of both cell-extrinsic and cell-intrinsic
factors. With regard to DOCK4, it should be noted that
additional factors acting in parallel to DOCK4 in medi-
ating TGF-b-promoted lung ADC cell extravasation and
metastasis likely come into play. While depletion of
DOCK4 impaired TGF-b-induced cell protrusive activity/
motility and extravasation of lung ADC cells, ectopic
expression of DOCK4 (at levels similar to those induced
by TGF-b) did not enhance the protrusive activity/motility
of these cells or their metastatic potential. In light of our
findings that DOCK4 is dispensable for TGF-b-induced
EMT in lung ADC cells, we envision that TGF-b drives
the activation of genes required for EMT and, in parallel,
the induction of DOCK4 expression and that the former
is a prerequisite for DOCK4’s subsequent enhancing
effects on the protrusive activity/motility and extravasa-
tion potential of lung ADC cells.
Finally, our data unveil that TGF-b/Smad-induced
DOCK4 promotes the protrusive activity and motility
of mesenchymal lung ADC cells via the activation of the
Rac1 GTPase. While Rac1 has been implicated previously
in cell motility and protrusion formation in different
tumor cell types (Reymond et al. 2013), so far, Rac1 has
been mainly linked to TGF-b via noncanonical pathways
(Zhang 2009). Here we showed that blockage of the
canonical Smad pathway greatly reduces TGF-b-induced
activation of Rac1 similarly to depletion of DOCK4. Thus,
our findings unveil a previously unrecognized link between
TGF-b/Smad and Rac1 signaling and identify DOCK4 as
a key player bridging the two pathways. Interestingly,
while multiple Rac-GEFs, including other DOCK family
members, are expressed in lung ADC cells, our findings
imply that they do not compensate for DOCK4 function, as
depletion of DOCK4 alone was sufficient to blunt TGF-
b-promoted lung ADC cell protrusive activity andmotility.
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Thus, DOCK4 likely provides specificity in signaling to
Rac1 activation downstream from TGF-b to control lung
ADC cell protrusion and motility. This is of particular
interest given that global and long-term inhibition of
Rac1 is well known to exert anti-proliferative effects on
not only tumor cells but also normal cells. Therefore, the
development of small molecules that specifically inhibit
DOCK4’s Rac-GEF activity or abrogate the interaction
between DOCK4 and Rac1 could present a valid thera-
peutic strategy in the treatment of lung ADC metastasis.
Materials and methods
Cell lines and human lung ADC TMAs
The lung ADC and breast cancer cell lines used in this study
were a gift from M. Wigler and R. Sordella (Cold Spring Harbor
Laboratory) and are listed in Supplemental Table 1. The cell lines
were grown and transduced with retroviral or lentiviral vectors
expressing the indicated shRNAs or cDNAs as described in the
Supplemental Material. Human lung ADC TMAs (TMA LC706
and TMA LC10013) used to assess levels of DOCK4 and
phospho-Smad3 expression were obtained from US Biomax,
Inc., as described in the Supplemental Material.
Animal studies
Five-week-old to 7-wk-old NSG mice (National Cancer Institute)
were used for all xenografting studies. Lung ADC cells stably
expressing firefly luciferase were injected intracardially for assess-
ment of multiorgan metastasis. Tumor growth in the lungs and
liver was assessed using intrathoracic and intrahepatic injections,
respectively. Bioluminescent signals were monitored and quanti-
fied using the IVIS-200 imaging system (Xenogen). Details of the
procedures are described in the Supplemental Material.
RNA and protein analysis, Rac1 activity, imaging, cellular
assays, public data set analysis, and statistics
RNA isolation, qPCR, coimmunoprecipitation, Rac activation
assays, immunofluorescence and image analysis, cellular assays,
ChIP-seq data analysis, lung ADC and ER-negative breast cancer
clinical data analysis, and statistic analysis are described in the
Supplemental Material.
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